Publications by authors named "Monet Howard"

Claim this Profile
C
Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A.
Arash Mahajerin, Imi Faghmous, Peter Kuebler, Monet Howard, Tao Xu

J Comp Eff Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.
Philippe Gevaert, Rebecca Saenz, Jonathan Corren, Joseph K Han, Joaquim Mullol, Monet Howard

J Allergy Clin Immunol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low immunogenicity of emicizumab in persons with haemophilia A.
Christophe Schmitt, Thomas Emrich, Sammy Chebon, Elena Fernandez, Claire Petry, Monet Howard

Haemophilia· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Michael U Callaghan, Claude Negrier, Ido Paz-Priel, Tiffany Chang, Sammy Chebon, Monet Howard

Blood· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis.
Toby M Maher, Ulrich Costabel, Marilyn K Glassberg, Yasuhiro Kondoh, Takashi Ogura, Monet Howard

Eur Respir J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
Cary D Austin, Melissa Gonzalez Edick, Ronald E Ferrando, Margaret Solon, Miriam Baca, Monet Howard

Clin Exp Allergy· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Philippe Gevaert, Theodore A Omachi, Jonathan Corren, Joaquim Mullol, Joseph Han, Monet Howard

J Allergy Clin Immunol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis